Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: A meta-analysis of published clinical trials
The DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
This review examines the evidence on the efficacy of calcitonin and etidronate in the prevention of osteoporosis and osteoporotic fractures. MEDLINE was searched for clinical trials calcitonin or etidronate and reviews of the treatment of postmenopausal osteoporosis. The reference sections of the papers retrieved were again searched for trials on the treatments of interest. Two people independently collected data from the trials that met the inclusion criteria of the study. Weighted means in the change in bone mineral density (BMD) and differences in vertebral fracture rates were computed for calcitonin and etidronate separately. The existence of publication bias was investigated by funnel plots of effect size against sample size. Eighteen clinical trials and calcitonin and six with etidronate were included in the meta-analysis. The pooled change in vertebral BMD at the end of the studies was 1.97 (95% CI 1.77 to 2.17) with calcitonin and 3.20 (95% CI 2.92 to 3.48) with etidronate. Pooled change in proximal femur BMD was 0.32 (95% CI -0.27 to 0.91) with calcitonin and 2.42 (95% CI 2.16 to 2.68) with etidronate. The aggregated number of vertebral fractures prevented by the treatment was 59.2 per 1000 patient-years (95% CI 55.1 to 63.3) for calcitonin and 28.3 (95% CI 26.2 to 30.4) for etidronate. With the available evidence we cannot establish the superiority of either of the two drugs for the treatment of postmenopausal osteoporosis. The clinical trials are particularly lacking in data on hip fracture, the most important consequence of osteoporosis. In this situation consideration of the relative costs of the drugs is prominent.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A number of small studies of intranasal or subcutaneous use of sCT showed increases in bone density, reduced number of vertebral fractures, and an association with reduction of the risk of hip fracture (26, 33, 110, 139), whereas others found no bone effects (12).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [26]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 95 · Cited by 53
Research works printed but not linked: 10
- Jackson RD. Cyclic etidronate for postmenopausal osteoporosis. Adv Endocrinol Metab 1991;2:1–21.
- Jenicek M. Méta-analyse en medicine. Québec: Edisem, 1987.
- Wolf FM. Meta-analysis: quantitative methods for research synthesis. Quantitative applications in the social sciences. Newbury Park, CA: Sage Publications, 1986.
- Gennari C, Chierichetti SM, Bigazzi S, et al. Comparative effects on bone mineral content of calcium and calcium plus salmon calcitonin given in two different regimes in postmenopausal osteoporosis. Curr Ther Res 1985;38:455–64.
- Meunier PJ. Calcitonina intranasal para la prevencion de la osteoporosis post-menopausica. Rev Med Univ Navarra 1992;37:200–4.
- Cristallini S, Pedetti M, Donatelli C, Gregorio F, Filipponi P. Effetto di differenti schemi terapeutici di tipo “coerente” sulla densita minerale ossea e sull'incidenza delle fratture vertebrali nell'osteoporosi avanzata. Recenti Prog Med 1993:84:336–45.
- Franceschini R, Bottaro P, Panopoulos C, Messina V. Long-term treatment with salmon calcitonin in postmenopausal osteoporosis. Curr Ther Res Clin Exp 1983;34:795–800.
- Agnusdei D, Gonnelli S, Camporeale A, Batignani T, Nardi P, lanes A, Gennari C. Efficacia clinica di un trattamento con calcitonina di salmone, somministrata per via endonasale per un anno, nell'osteoporosi postmenopausale stabilizzata. Minerva Endocrinol 1989;14:169–76.
- Peyron R, Serrurier D, Edouard C, Ghozlan R, Mayoux-Benhamou A, Meunier PJ, CIGOP. Treatment of high remodeling vertebral osteoporosis with human calcitonin: a two year double-blind placebo-controlled trial in 93 patients. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Copenhagen: Osteo-press, 1990:1430–3.
- Abellan Perez M, Bayina Garcia FJ, Calabozo M, et al. Estudio comparativo multicentrico de la calcitonina sintetica de salmon administrada por via nasal en el tratamiento de la osteoporosis postmenopausica establecida. An Med Interna 1995;12:12–6.
Metadata
- Authors
- Cardona, J. M., & Pastor, E.
- Affiliations
- Generalitat Valenciana (ES)
- Venue
- Osteoporosis International
- Published
- 1997-05
- Volume
- 7
- Issue
- 3
- Pages
- 165-174
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W1982169278
- Cited by
- 53
- References
- 95
- Citations by year
- 2021: 1 · 2020: 1 · 2018: 1 · 2017: 2 · 2015: 1 · 2013: 1
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- calcitonin, etidronate, postmenopausal osteoporosis, osteoporotic fractures, vertebral fractures, bone mineral density, proximal femur, hip fracture, drug efficacy comparison, publication bias
- MeSH terms
- Calcitonin, Female, Fractures, Spontaneous, Humans, Middle Aged, Risk Factors, Etidronic Acid, Bone Density, Osteoporosis, Postmenopausal, Randomized Controlled Trials as Topic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: A meta-analysis of published clinical trials. https://app.cochat.ai/papers/10.1007/bf01622285
- The paper
- Cardona, J. M., & Pastor, E. (1997). Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: A meta-analysis of published clinical trials. Osteoporosis International. https://doi.org/10.1007/bf01622285
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.